Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
Bruno Dubois, Nicolas Villain, Giovanni B. Frisoni, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 6, pp. 484-496
Open Access | Times Cited: 690

Showing 26-50 of 690 citing articles:

Cognitive effects of Lewy body pathology in clinically unimpaired individuals
Sebastian Palmqvist, Marcello Rossi, Sara Hall, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 1971-1978
Open Access | Times Cited: 78
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment
Cherie Strikwerda‐Brown, Diana A. Hobbs, Julie Gonneaud, et al.
JAMA Neurology (2022) Vol. 79, Iss. 10, pp. 975-975
Open Access | Times Cited: 77
Clinical effects of Lewy body pathology in cognitively impaired individuals
Corinne Quadalti, Sebastian Palmqvist, Sara Hall, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 1964-1970
Open Access | Times Cited: 77
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation
Bruno Dubois, Nicolas Villain, Lon S. Schneider, et al.
JAMA Neurology (2024)
Closed Access | Times Cited: 61
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?
Markku Kurkinen, Michał Fułek, Katarzyna Fułek, et al.
Biomolecules (2023) Vol. 13, Iss. 3, pp. 453-453
Open Access | Times Cited: 47
Understanding neuropsychiatric symptoms in Alzheimer’s disease: challenges and advances in diagnosis and treatment
Andrew Pless, Destany Ware, Shalini Saggu, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 43
Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 42
Alzheimer’s disease early diagnostic and staging biomarkers revealed by large-scale cerebrospinal fluid and serum proteomic profiling
Qing‐Qing Tao, Xue Cai, Yan‐Yan Xue, et al.
The Innovation (2024) Vol. 5, Iss. 1, pp. 100544-100544
Open Access | Times Cited: 22
Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank
Xiaofei Wang, Ziyan Shi, Yuhan Qiu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 21
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 9
Clinical criteria for limbic‐predominant age‐related TDP‐43 encephalopathy
David A. Wolk, Peter T. Nelson, Liana G. Apostolova, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 3
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Journal of Nuclear Medicine (2025), pp. jnumed.124.268756-jnumed.124.268756
Closed Access | Times Cited: 2
Lecanemab approval in EU: what should we be ready for?– the EANM perspective
Igor Yakushev, Antoine Verger, Matthias Brendel, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2025)
Open Access | Times Cited: 2
Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use
Michael Schöll, Agathe Vrillon, Takeshi Ikeuchi, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100056-100056
Open Access | Times Cited: 2
Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery
Francesca R. Buccellato, Marianna D’Anca, Chiara Fenoglio, et al.
Antioxidants (2021) Vol. 10, Iss. 9, pp. 1353-1353
Open Access | Times Cited: 97
Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
Marco Bucci, Konstantinos Chiotis, Agneta Nordberg
Molecular Psychiatry (2021) Vol. 26, Iss. 10, pp. 5888-5898
Open Access | Times Cited: 88
Research Criteria for the Behavioral Variant of Alzheimer Disease
Rik Ossenkoppele, Ellen H. Singleton, Colin Groot, et al.
JAMA Neurology (2021) Vol. 79, Iss. 1, pp. 48-48
Open Access | Times Cited: 88
Can we learn lessons from the FDA’s approval of aducanumab?
Kathy Liu, Robert Howard
Nature Reviews Neurology (2021) Vol. 17, Iss. 11, pp. 715-722
Open Access | Times Cited: 87
Recent update on the heterogeneity of the Alzheimer’s disease spectrum
K. A. Jellinger
Journal of Neural Transmission (2021) Vol. 129, Iss. 1, pp. 1-24
Closed Access | Times Cited: 86
MRI Deep Learning-Based Solution for Alzheimer’s Disease Prediction
Cristina L. Saratxaga, Iratxe Moya, Artzai Picón, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 9, pp. 902-902
Open Access | Times Cited: 79
Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios
Femke H. Bouwman, Giovanni B. Frisoni, Sterling C. Johnson, et al.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 65
High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects
Nicolas Villain, Vincent Planche, Raymond Levy
Revue Neurologique (2022) Vol. 178, Iss. 10, pp. 1011-1030
Open Access | Times Cited: 64
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Sonalika Bhalla, Sidharth Mehan, Andleeb Khan, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 142, pp. 104896-104896
Closed Access | Times Cited: 62
Alzheimer’s disease clinical trial update 2019–2021
Joseph Pleen, Ryan Townley
Journal of Neurology (2021) Vol. 269, Iss. 2, pp. 1038-1051
Closed Access | Times Cited: 61
Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort
Vincent Planche, Vincent Bouteloup, Isabelle Pellegrin, et al.
Neurology (2022) Vol. 100, Iss. 5
Open Access | Times Cited: 61

Scroll to top